Statements and Press Releases
Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).
WASHINGTON, D.C. — June 3, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today released an update on a Phase 1 clinical trial of its vaccine candidate to prevent intestinal schistosomiasis, Sm-TSP-2/Alhydrogel®. Schistosomiasis is one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poorest communities. The Sabin PDP is based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine (BCM) in Houston, Texas.
On June 11, 2014, Congressman Chris Smith (R-NJ) introduced a bipartisan bill in the House of Representatives to support the control and elimination of neglected tropical diseases (NTDs) in the United States and abroad. H.R. 4847, the “End Neglected Tropical Diseases Act,” calls for the expansion of USAID’s NTD program; increased U.S. Government advocacy for NTDs among international development and financing institutions; reporting from the U.S. Department of Health and Human Services on NTDs in the United States; the creation of one or more NTD centers of excellence to increase research and development (R&D); and the establishment of a panel on intestinal worm infections, one of the most pervasive NTDs.
Program intends to develop and test a vaccine against all four major parasitic worm infectio